Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Recordati completes double-blind portion of phase III Urief trial for BPH

Sep. 28, 2007

Allergan to acquire Esprit Pharma and partner with Indevus on Sanctura brand

Sep. 21, 2007

Palatin reacquires full rights to bremelanotide program

Sep. 13, 2007

Positive results for Plethora Solutions' phase II study of PSD-597 for interstitial cystitis

Sep. 10, 2007

Novel ATP-sensitive potassium channel activators emerge from Janssen R&D

Sep. 6, 2007

Modulation of mGlu5 receptor activity may provide benefit in incontinence and overactive bladder

Sep. 4, 2007

Plans delayed for phase III study of bremelanotide for ED

Sep. 3, 2007

Recent Takeda patent reports novel tachykinin NK1 antagonists

Sep. 3, 2007

Orexo's treatment for nocturia/incontinence enters phase I

Aug. 31, 2007

BioLineRx Inlicenses acute kidney injury treatment

Aug. 30, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...